Daraxonrasib succeeded in a Phase 3 registrational trial for pancreatic cancer patients, Revolution Medicines reported Monday. The KRAS inhibitor’s pivotal win positions the company well for what comes next.
The Phase 3 result gives Revolution Medicines the efficacy data it needs to plan the program’s next phase. Pancreatic cancer is one of the hardest indications in oncology. A survival-doubling result in a registrational trial doesn’t come around often in this space, and it changes the commercial value of a pipeline asset overnight.
KRAS mutations are among the most common drivers of pancreatic cancer, making daraxonrasib’s mechanism central to the disease. A cleared inhibitor in this indication would put Revolution Medicines in one of oncology’s most commercially important treatment areas, where durable advances have been rare.
The company said it plans next steps following the Phase 3 readout. Full data and a submission timeline weren’t disclosed in Monday’s initial report.
— Sarah Chen